Mahendra Deonarain PhD, DPhil

Dr Mahendra Deonarain studied at Imperial College and Cambridge University, where he carried outa  PhD research into protein engineering. From 1997-2011, Dr Deonarain was a Principal Investigator and Reader in Antibody Technology at Imperial College, which led to some novel technologies being developed commercially. Dr Deonarain now retains honorary links with Imperial College. He has published over 70 papers and patents in protein/antibody engineering/conjugates. In 2001, he co-founded PhotoBiotics to develop a form of targeted photodynamic therapy using antibody fragments optimized for bio-conjugation (OptiLink technology). This is now at Antikor Biopharma, where he is CEO/CSO, leading a team to develop the next generation of antibody-fragment-based ADCs for solid tumours based on OptiLink.